Project Details
Description
Multicenter, randomized, double-blind, placebo controlled, and parallel group Phase III trial to assess the effects of oral TRPC6 Inhibitor in adult and pediatric patients with Primary Focal Segmental Glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants
| Status | Active |
|---|---|
| Effective start/end date | 1/1/25 → … |
Collaborative partners
- HCA Healthcare
- Boehringer Ingelheim (lead)